It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA).
- Could you give us a brief overview of the clinical trial program that has led to the approval of aducanumab for Alzheimer’s disease? (0:09)
- Could you tell us more about the ongoing EMBARK study? (1:38)
- Why has aducanumab succeeded when so many other drugs have failed late stage clinical trials? (2:07)
- What are the challenges and opportunities presented by this approval? (4:01)
- What questions remain unanswered and what future studies are planned? (5:30)
Disclosures: Marwan Sabbagh receives research support from the NIH and the Keep Memory Alive Foundation; consulting agreements with Alzheon, Biogen, Cortexyme, Danone, Neurotrope, Regenron, Stage 2 Innovations, Acadia, and Roche-Genentech; stock options in Brain Health Inc., NeuroReserve, NeuroTau, Optimal Cognitive Health Co., uMethod Health,Versanum Inc. and Athira.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!